Alphavax, Incorporated

Liquidia Technologies, Inc.

Bolyn Hubby

Jonathan F Smith

Jon O Rayner

Elizabeth A Reap

Laura Copp

Peter Berglund

Whitney Ellis

Jesse White

Andrew Murphy

Samantha Roth

Jeff Kindig

Ashley Galloway

The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.

TC-83-derived alphavirus vectors, particles and methods

The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.

Alphavirus replicon particles matched to protein antigens as immunological adjuvants

The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.

Alphavirus replicon particles as immunological adjuvants

Growing community of inventors

Chapel Hill, NC, United States of America

Bolyn Hubby